ArticleProceedings of the National Academy of Sciences of the United States of America2021
Identification of fluoxetine as a direct NLRP3 inhibitor to treat atrophic macular degeneration.
Open access · greenAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 69 citations in OpenAlex.
- The role of NLRP3 inflammasome in age-related macular degeneration: mechanisms and therapeutic prospects.Frontiers in aging neuroscience · 2026Review
- Genetic removal of Nlrp3 protects against age-related and R345W Efemp1-induced basal laminar deposit formation.Cell death & disease · 2025Article
- NLRP3 Activation With Bisphosphonate Use and the Risk of Incident Age-Related Macular Degeneration.Investigative ophthalmology & visual science · 2025Article
- Fluoxetine exerts anti-proliferative effect in human epidermal keratinocytes.Archives of dermatological research · 2025Article
- Article
- Different Therapeutic Approaches for Dry and Wet AMD.International journal of molecular sciences · 2024Review
- Tissue Engineering and Ophthalmology.Turkish journal of ophthalmology · 2024Review
- Depression and Eye Disease-A Narrative Review of Common Underlying Pathophysiological Mechanisms and their Potential Applications.Journal of clinical medicine · 2024Review
- Cancer-derived exosomal Alu RNA promotes colorectal cancer progression.Experimental & molecular medicine · 2024Article
- Alzheimer Disease Treatment With Acetylcholinesterase Inhibitors and Incident Age-Related Macular Degeneration.JAMA ophthalmology · 2024Observational
- Circulating Toll-Like Receptor 4, Nucleotide-Binding Oligomerization Domain-Like Receptor Protein 3, and Cytokines in Patients with Bipolar Depression: A Case-Control Study.Alpha psychiatry · 2023Article
- Fluoxetine restrains allergic inflammation by targeting an FcɛRI-ATP positive feedback loop in mast cells.Science signaling · 2023Article
- A bioinspired and high-strengthed hydrogel for regeneration of perforated temporomandibular joint disc: Construction and pleiotropic immunomodulatory effects.Bioactive materials · 2023Article
- Portrayal of NLRP3 Inflammasome in Atherosclerosis: Current Knowledge and Therapeutic Targets.International journal of molecular sciences · 2023Review
- Repurposing medications for treatment of age-related macular degeneration: Insights from novel approaches to data mining.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- Association between Fluoxetine Use and Overall Survival among Patients with Cancer Treated with PD-1/L1 Immunotherapy.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Ultra-rare complement factor 8 coding variants in families with age-related macular degeneration.iScience · 2023Article
- Inflammation and Epstein-Barr Virus at the Crossroads of Multiple Sclerosis and Post-Acute Sequelae of COVID-19 Infection.Viruses · 2023Review
- Beyond "Psychotropic": Repurposing Psychiatric Drugs for COVID-19, Alzheimer's Disease, and Cancer.The Journal of clinical psychiatry · 2023Review
- SSRIs differentially modulate the effects of pro-inflammatory stimulation on hippocampal plasticity and memory via sigma 1 receptors and neurosteroids.Translational psychiatry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 8 institutions in 3 countries.
Meenakshi AmbatiCenter for Advanced Vision Science, University of Virginia School of Medicine, Charlottesville, VA 22901.ORCID 0000-0002-4047-5268
Ivana ApicellaCenter for Advanced Vision Science, University of Virginia School of Medicine, Charlottesville, VA 22901.ORCID 0000-0002-2716-5003
Shao-Bin WangCenter for Advanced Vision Science, University of Virginia School of Medicine, Charlottesville, VA 22901.ORCID 0000-0002-6699-9406
Siddharth NarendranCenter for Advanced Vision Science, University of Virginia School of Medicine, Charlottesville, VA 22901.ORCID 0000-0002-9220-8049
Hannah LeungCenter for Advanced Vision Science, University of Virginia School of Medicine, Charlottesville, VA 22901.
Felipe PereiraCenter for Advanced Vision Science, University of Virginia School of Medicine, Charlottesville, VA 22901.ORCID 0000-0001-8884-2816
Yosuke NagasakaCenter for Advanced Vision Science, University of Virginia School of Medicine, Charlottesville, VA 22901.
Peirong HuangCenter for Advanced Vision Science, University of Virginia School of Medicine, Charlottesville, VA 22901.ORCID 0000-0003-2793-1473
Akhil VarshneyCenter for Advanced Vision Science, University of Virginia School of Medicine, Charlottesville, VA 22901.ORCID 0000-0003-0759-0982
Kirstie L BakerDoheny Eye Institute, Los Angeles, CA 90033.ORCID 0000-0003-3953-4352
Kenneth M MarionDoheny Eye Institute, Los Angeles, CA 90033.ORCID 0000-0003-1275-5729
Mehrdad ShadmehrDepartment of Chemistry, University of Virginia, Charlottesville, VA 22904.
Cliff I StainsDepartment of Chemistry, University of Virginia, Charlottesville, VA 22904.ORCID 0000-0002-3165-4539
Brian C WernerDepartment of Orthopaedic Surgery, University of Virginia School of Medicine, Charlottesville, VA 22908; gelfand@virginia.edu magagnol@mailbox.sc.edu bcw4x@hscmail.mcc.virginia.edu.ORCID 0000-0002-7956-2123
Srinivas R SaddaDoheny Eye Institute, Los Angeles, CA 90033.
Ethan W TaylorDepartment of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, NC 27412.ORCID 0000-0002-0021-3044
S Scott SuttonDepartment of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, SC 29208.ORCID 0000-0002-3889-6178
Joseph MagagnoliDepartment of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, SC 29208; gelfand@virginia.edu magagnol@mailbox.sc.edu bcw4x@hscmail.mcc.virginia.edu.
Bradley D GelfandCenter for Advanced Vision Science, University of Virginia School of Medicine, Charlottesville, VA 22901; gelfand@virginia.edu magagnol@mailbox.sc.edu bcw4x@hscmail.mcc.virginia.edu.ORCID 0000-0003-4619-9409
University of Virginia · USDoheny Eye Institute · USUniversity of South Carolina · USAravind Eye Hospital · INCenter for Digital Image Evaluation · USUniversity of California, Los Angeles · USUniversity of North Carolina at Greensboro · USUniversity of Virginia Cancer Center
Funding
Visual system and cognitive biology in normal animals versus in an animal model of Alzheimer's disease with or without diabetes treated with solo or dual inflammasome inhibitorsR01EY031039 · NEI · UNIVERSITY OF VIRGINIA · PI AMBATI, JAYAKRISHNA, GELFAND, BRADLEY DAVID · 2020 to 2024
$3.2MAntigen-independent suppression of ocular angiogenesis via the Fc receptorR01EY028027 · NEI · UNIVERSITY OF VIRGINIA · PI AMBATI, JAYAKRISHNA, GELFAND, BRADLEY DAVID · 2018 to 2022
$2.2MDICER1 deficiency in aberrant chorioretinal neovascularization - Administrative Supplement OKT RequestR01EY032512 · NEI · UNIVERSITY OF VIRGINIA · PI GELFAND, BRADLEY DAVID · 2021 to 2024
$2.1MChemical Approaches for Interrogating Fundamental Biomedical ProcessesR35GM119751 · NIGMS · UNIVERSITY OF VIRGINIA · PI STAINS, CLIFF I · 2016 to 2020
$1.8MNEI NIH HHS R01 EY028027NEI NIH HHS R01 EY031039NEI NIH HHS R01 EY032512NIGMS NIH HHS R35 GM119751
Abstract
The atrophic form of age-related macular degeneration (dry AMD) affects nearly 200 million people worldwide. There is no Food and Drug Administration (FDA)-approved therapy for this disease, which is the leading cause of irreversible blindness among people over 50 y of age. Vision loss in dry AMD results from degeneration of the retinal pigmented epithelium (RPE). RPE cell death is driven in part by accumulation of
Indexed as
Alu ElementsAnimalsAntidepressive Agents, Second-GenerationBlindnessCell LineCytokinesDepressionDisease Models, AnimalDrug RepositioningFluoxetineInflammasomesMacrophagesMacular DegenerationMiceMice, Inbred C57BLNLR Family, Pyrin Domain-Containing 3 ProteinAntidepressive Agents, Second-GenerationCytokinesFluoxetineInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseRNAfluoxetinehealth insurance databasesmacular degenerationmolecular modelingretina
Identifiers
What Socratic holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.